Comprehensive Guide to Peptide Receptor Radionuclide Therapy (PRRNT) in Neuroendocrine Tumours (NET)

Peptide Receptor Radionuclide Therapy (PRRNT) is a targeted approach using radiopharmaceuticals to deliver radiation to neuroendocrine tumors expressing specific receptors. This therapy, involving 90Y-DOTATOC or 177Lu-DOTATATE, has shown promising results in treating NETs with minimal side effects.

0 views • 36 slides